Kura Oncology (KURA) Current Deferred Revenue (2024 - 2026)

Kura Oncology (KURA) has 3 years of Current Deferred Revenue data on file, last reported at $47.7 million in Q1 2026.

• Quarterly Current Deferred Revenue rose 16.79% year-over-year to $47.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47.7 million (up 16.79% YoY) and the FY2025 annual result came in at $49.0 million, up 101.82% from the prior year.
• Current Deferred Revenue slipped to $47.7 million in Q1 2026 per KURA's latest filing, from $49.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $49.4 million in Q2 2025 and bottomed at $24.3 million in Q4 2024.
• The 3-year median for Current Deferred Revenue is $48.2 million (2025), against an average of $43.3 million.
• The widest annual swing landed in 2025, when Current Deferred Revenue soared 101.82%; it then grew 16.79% in 2026.
• Tracing KURA's Current Deferred Revenue over 3 years: stood at $24.3 million in 2024, then surged by 101.82% to $49.0 million in 2025, then slipped by 2.61% to $47.7 million in 2026.
• Per Business Quant, the three latest KURA Current Deferred Revenue figures stand at $47.7 million (Q1 2026), $49.0 million (Q4 2025), and $48.8 million (Q3 2025).

Peer Comparison